0001209191-18-021358.txt : 20180323
0001209191-18-021358.hdr.sgml : 20180323
20180323091759
ACCESSION NUMBER: 0001209191-18-021358
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180322
FILED AS OF DATE: 20180323
DATE AS OF CHANGE: 20180323
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cagle Gerald D.
CENTRAL INDEX KEY: 0001589991
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37783
FILM NUMBER: 18708524
MAIL ADDRESS:
STREET 1: 135 U.S. HIGHWAY 206
STREET 2: SUITE 15
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Clearside Biomedical, Inc.
CENTRAL INDEX KEY: 0001539029
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 452437375
STATE OF INCORPORATION: GA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 900 NORTH POINT PARKWAY
STREET 2: SUITE 200
CITY: ALPHARETTA
STATE: 2Q
ZIP: 30005
BUSINESS PHONE: 678-270-3631
MAIL ADDRESS:
STREET 1: 900 NORTH POINT PARKWAY
STREET 2: SUITE 200
CITY: ALPHARETTA
STATE: 2Q
ZIP: 30005
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-03-22
0
0001539029
Clearside Biomedical, Inc.
CLSD
0001589991
Cagle Gerald D.
C/O CLEARSIDE BIOMEDICAL, INC.
900 NORTH POINT PARKWAY, SUITE 200
ALPHARETTA
GA
30005
1
0
0
0
Common Stock
2018-03-22
4
P
0
7500
11.89
A
23441
D
Common Stock
14064
I
See Footnote
This transaction was executed in multiple trades at prices ranging from $11.83 to $11.95, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Cagle Business Interests, Ltd. is the record holder of these securities. The reporting person is the general partner of Cagle Business Interests, Ltd. and may be deemed to share voting and dispositive power over these securities. The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
/s/ Brian F. Leaf, Attorney-in-Fact
2018-03-23